Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Aine Carol Burke & Frank James Giles. (2011) Elacytarabine – lipid vector technology overcoming drug resistance in acute myeloid leukemia. Expert Opinion on Investigational Drugs 20:12, pages 1707-1715.
Read now
Read now
GodefridusJ. Peters, AukeD. Adema, IreneV. Bijnsdorp & MaritL. Sandvold. (2011) Lipophilic Prodrugs and Formulations of Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer. Nucleosides, Nucleotides & Nucleic Acids 30:12, pages 1168-1180.
Read now
Read now
Bhupender S Chhikara & Keykavous Parang. (2010) Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opinion on Drug Delivery 7:12, pages 1399-1414.
Read now
Read now
A.D. Adema, N. Losekoot, K. Smid, I. Kathmann, F. Myhren, M.L. Sandvold & G.J. Peters. (2010) Induction of Resistance to the Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells. Nucleosides, Nucleotides & Nucleic Acids 29:4-6, pages 394-399.
Read now
Read now
Marit
Liland Sandvold, Carlos Galmarini, Finn Myhren & Godefridus Peters. (2010) The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues. Nucleosides, Nucleotides & Nucleic Acids 29:4-6, pages 386-393.
Read now
Read now
Articles from other publishers (16)
Bogdan-Florin Craciun, Isabela-Andreea Sandu, Dragos Peptanariu & Mariana Pinteala. (2023) Novel Nanotherapeutic Systems Based on PEGylated Squalene Micelles for Enhanced In Vitro Activity of Methotrexate and Cytarabine. Polymers 15:21, pages 4225.
Crossref
Crossref
Xia Lin, Chunxian Liang, Lianjia Zou, Yanchun Yin, Jianyi Wang, Dandan Chen & Weisen Lan. (2021) Advance of structural modification of nucleosides scaffold. European Journal of Medicinal Chemistry 214, pages 113233.
Crossref
Crossref
Nadia Fattahi, Mohammad-Ali Shahbazi, Aziz Maleki, Mehrdad Hamidi, Ali Ramazani & Hélder A. Santos. (2020) Emerging insights on drug delivery by fatty acid mediated synthesis of lipophilic prodrugs as novel nanomedicines. Journal of Controlled Release 326, pages 556-598.
Crossref
Crossref
Bingjun Sun, Cong Luo, Weiping Cui, Jin Sun & Zhonggui He. (2017) Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy. Journal of Controlled Release 264, pages 145-159.
Crossref
Crossref
Dong Zhang, Dongpo Li, Lei Shang, Zhonggui He & Jin Sun. (2016) Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption. International Journal of Pharmaceutics 511:1, pages 161-169.
Crossref
Crossref
Peter Alexander, Gregory Kucera & Timothy S. Pardee. (2016) Improving nucleoside analogs via lipid conjugation: Is fatter any better?. Critical Reviews in Oncology/Hematology 100, pages 46-56.
Crossref
Crossref
Lindsay A. M. Rein & David A. Rizzieri. (2014) Clinical potential of elacytarabine in patients with acute myeloid leukemia. Therapeutic Advances in Hematology 5:6, pages 211-220.
Crossref
Crossref
Courtney D DiNardo, Susan O’Brien, Varsha V Gandhi & Farhad Ravandi. (2013) Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncology 9:8, pages 1073-1082.
Crossref
Crossref
Elodie Moysan, Guillaume Bastiat & Jean-Pierre Benoit. (2012) Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications. Molecular Pharmaceutics 10:2, pages 430-444.
Crossref
Crossref
Auke D. Adema, Kees Smid, Nienke Losekoot, Richard J. Honeywell, Henk M. Verheul, Finn Myhren, Marit L. Sandvold & Godefridus J. Peters. (2011) Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Investigational New Drugs 30:5, pages 1908-1916.
Crossref
Crossref
Susan O'Brien, David A. Rizzieri, Norbert Vey, Farhad Ravandi, Utz O. Krug, Mikkael A. Sekeres, Mike Dennis, Adriano Venditti, Donald A. Berry, Tove Flem Jacobsen, Karin Staudacher, Trygve Bergeland & Francis J. Giles. (2012) Elacytarabine has single‐agent activity in patients
with advanced acute myeloid leukaemia. British Journal of Haematology 158:5, pages 581-588.
Crossref
Crossref
F J Giles, N Vey, D Rizzieri, F Ravandi, T Prebet, G Borthakur, T F Jacobsen, S Hagen, B Nilsson & S O'Brien. (2012) Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. Leukemia 26:7, pages 1686-1689.
Crossref
Crossref
Didier Desmaële, Ruxandra Gref & Patrick Couvreur. (2012) Squalenoylation: A generic platform for nanoparticular drug delivery. Journal of Controlled Release 161:2, pages 609-618.
Crossref
Crossref
Lawrence Rajendran, Vinod Udayar & Zoë V. Goodger. (2012) Lipid-anchored drugs for delivery into subcellular compartments. Trends in Pharmacological Sciences 33:4, pages 215-222.
Crossref
Crossref
Andries M. Bergman, Auke D. Adema, Jan Balzarini, Skjalg Bruheim, Iduna Fichtner, Paul Noordhuis, Øystein Fodstad, Finn Myhren, Marit L. Sandvold, Hans R. Hendriks & Godefridus J. Peters. (2010) Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Investigational New Drugs 29:3, pages 456-466.
Crossref
Crossref
L. Harivardhan Reddy & Patrick Couvreur. (2009) Squalene: A natural triterpene for use in disease management and therapy. Advanced Drug Delivery Reviews 61:15, pages 1412-1426.
Crossref
Crossref